PHARMACOLOGY UPDATE

Mepolizumab Injection (Nucala)

January 15, 2016

Mepolizumab is indicated for add-on maintenance treatment of adult patients ≥ 12 years of age with severe asthma and with an eosinophilic phenotype.

Issue Date: January 15, 2016

Table of Contents

Financial Disclosure: Internal Medicine Alert’s editor Stephen Brunton, MD, is a retained consultant for Abbott, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Exact Sciences, Janssen, Lilly, Mylan, Novo Nordisk, and Teva; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing editor Louis Kuritzky, MD, is a retained consultant for AbbVie, Allergan, AstraZeneca, Janssen, Lilly, Lundbeck, Medscape, Novo Nordisk, and Sanofi Aventis; he serves on the speakers bureau of Lilly and Lundbeck. Peer reviewer Gerald Roberts, MD; executive editor Leslie Coplin; and associate managing editor Jonathan Springston report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements